42 results on '"Wahlin, Björn Engelbrekt"'
Search Results
2. ADAR1-mediated RNA editing promotes B cell lymphomagenesis
3. Δ9-THC and CBD in Plasma, Oral Fluid, Exhaled Breath, and Urine from 23 Patients Administered Sativex.
4. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis
5. Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy
6. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome
7. Splenic marginal zone lymphoma in Sweden 2000–2020: Increasing rituximab use and better survival in the elderly
8. Δ9-THC and CBD in Plasma, Oral Fluid, Exhaled Breath, and Urine from 23 Patients Administered Sativex
9. Supplementary Data from Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
10. Supplementary Materials and Methods from T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
11. Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden
12. The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016
13. G‐CSF mobilized peripheral blood stem cell collection for allogeneic transplantation in healthy donors: Analysis of factors affecting yield
14. Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia
15. High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse
16. Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience
17. Real‐world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000–2014, focusing on patients aged >60 years
18. Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results
19. RNA-Editing-Initiated MAVS Signaling is a Key Epitranscriptomic Alteration in Human B Cell Lymphoma
20. Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study
21. Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma
22. Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 – azacitidine induces only lymphoma remission
23. Reply to M. Sorigue et al
24. Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up
25. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
26. Chemotherapeutic intensity and survival differences in young patients with diffuse large B‐cell lymphoma: a Swedish Lymphoma Registry study
27. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era
28. Combined Clinical and Gene Expression Score Identifies Follicular Lymphoma Patients with High Risk of Transformation in the Rituximab Era
29. Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation
30. T-Cell Frequencies In MCL Are Of Prognostic Importance In a Large Population-Based Cohort
31. Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy
32. Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab
33. Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results
34. T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
35. A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1–Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages
36. Several Immune Cell Subsets Are Associated with Outcome in the Microenvironment of Follicular Lymphoma.
37. CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma
38. Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.
39. Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy.
40. Long-Term Follow-up of Patients with Indolent Lymphoma after First Line Therapy with Rituximab As Single Agent or in Combination with Interferon-α2a
41. Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML
42. Δ 9 -THC and CBD in Plasma, Oral Fluid, Exhaled Breath, and Urine from 23 Patients Administered Sativex.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.